secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-08-07T20:43:59+00:00
Accession:  0001703057-26-000049
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera to release Phase 2 top-line data for ABCL635 (menopause VMS) on Aug 10, 2026
--------------------------------------------------------------------------------

- Top-line data from Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms due to menopause to be released before market open on Monday, August 10, 2026.
- Investor conference call and webcast scheduled at 4:30 a.m. PT / 7:30 a.m. ET on the same day.
- No trial results disclosed in this announcement; data release is upcoming catalyst.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/0001703057-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/abcl-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer